Therapeutic Approaches for Malignant Gliomas

Malignant gliomas, particularly glioblastoma, represent one of the most formidable challenges in neuro-oncology due to their diffuse infiltration, molecular heterogeneity and robust mechanisms of therapy resistance. Current standard treatment comprises maximal safe surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide. Despite incremental gains in survival, almost all tumours recur, driven by subpopulations of stem-like cells, tumour hypoxia and an immunosuppressive microenvironment. Emerging strategies aim to exploit molecular vulnerabilities, including receptor tyrosine kinase aberrations, dysregulated metabolic pathways and epigenetic alterations. Advances in precision radiotherapy, targeted radionuclide approaches and immunomodulation—such as checkpoint inhibitors and engineered cellular therapies—seek to overcome the protective niche of the blood–brain barrier and the stromal compartment. Integration of multimodal biomarkers, innovative drug-delivery systems and adaptive trial designs offers renewed promise for durable disease control.

Research from Nature Portfolio

Recent studies have articulated the critical barriers to curing high-grade gliomas, emphasising seven key challenges: intratumoural heterogeneity, neural microenvironmental constraints, the stem-cell niche, the blood–brain barrier, dynamic immunosuppression, therapy-induced tumour adaptation and the need for integrated multidisciplinary research. These insights provide a framework for prioritising research efforts and resource allocation. Complementing this, a proteomic and metabolic classification of glioblastoma stem-like cells has delineated two major subtypes—pro-neural-like and mesenchymal-like—with distinct activation of pathways such as SRC kinase and the mTOR axis. Stratifying patients by these molecular signatures offers a rationale for pathway-selective inhibitors and personalised therapeutic regimens, guiding future clinical trial designs.

Therapeutic Approaches for Malignant Gliomas publication trend

The graph below shows the total number of articles in therapeutic approaches for malignant gliomas across all publications each year (not limited to Nature Index journals).

Technical terms

Malignant glioma: An aggressive primary brain tumour arising from glial cells, with high propensity for invasion and recurrence.

Glioblastoma stem cells: A subpopulation of tumour cells possessing self-renewal capacity and driving resistance to conventional treatments.

Hypoxia-inducible factors (HIFs): Transcription factors activated under low oxygen that orchestrate adaptive responses promoting tumour survival.

Extracellular vesicles (EVs): Membrane-bound particles released by cells that transfer proteins and nucleic acids to modulate recipient cell behaviour.

Proteomic profiling: Comprehensive analysis of protein expression and modification to identify disease subtypes and therapeutic targets.

Targeted alpha therapy: A treatment modality using α-particle–emitting radionuclides linked to tumour-specific ligands for high-precision cell killing.

References

1. Challenges to curing primary brain tumours. Nature Reviews Clinical Oncology (2019).
2. Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. Scientific Reports (2016).
3. Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme. Cell Death & Disease (2024).
4. Changes Induced by P2X7 Receptor Stimulation of Human Glioblastoma Stem Cells in the Proteome of Extracellular Vesicles Isolated from Their Secretome. Cells (2024).
5. Radiation-Induced Alterations in the Recurrent Glioblastoma Microenvironment: Therapeutic Implications. Frontiers in Oncology (2018).
6. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue. European Journal of Nuclear Medicine and Molecular Imaging (2018).